LENZ Therapeutics (LENZ)
NASDAQ:LENZ
Total Valuation
LENZ Therapeutics has a market cap or net worth of $303.20M. The enterprise value is $278.37M.
Market Cap$303.20M
Enterprise Value$278.37M
Share Statistics
LENZ Therapeutics has 31,354,395 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,354,395
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
LENZ Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -32.01%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-32.01%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee3.18M
Profits Per Employee-13.69M
Employee Count6
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of LENZ Therapeutics is ―. LENZ Therapeutics’s PEG ratio is -0.26.
PE Ratio―
PS Ratio24.15
PB Ratio1.62
Price to Fair Value1.62
Price to FCF-6.59
Price to Operating Cash Flow-4.34
PEG Ratio-0.26
Income Statement
In the last 12 months, LENZ Therapeutics had revenue of 19.09M and earned -82.13M in profits. Earnings per share was -2.85.
Revenue19.09M
Gross Profit18.67M
Operating Income-91.14M
Pretax Income-81.63M
Net Income-82.13M
EBITDA-91.14M
Earnings Per Share (EPS)-2.85
Cash Flow
In the last 12 months, operating cash flow was -69.17M and capital expenditures -827.00K, giving a free cash flow of -70.00M billion.
Operating Cash Flow-69.17M
Free Cash Flow-70.00M
Free Cash Flow per Share-2.23
Dividends & Yields
LENZ Therapeutics pays an annual dividend of $7.21, resulting in a dividend yield of ―
Dividend Per Share$7.21
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.50
52-Week Price Change-50.41%
50-Day Moving Average13.08
200-Day Moving Average26.82
Relative Strength Index (RSI)39.31
Average Volume (3m)1.07M
Important Dates
LENZ Therapeutics upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateMar 25, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
LENZ Therapeutics as a current ratio of 13.80, with Debt / Equity ratio of 0.12%
Current Ratio13.80
Quick Ratio13.80
Debt to Market Cap<0.01
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, LENZ Therapeutics has paid 502.00K in taxes.
Income Tax502.00K
Effective Tax Rate>-0.01
Enterprise Valuation
LENZ Therapeutics EV to EBITDA ratio is -4.79, with an EV/FCF ratio of -6.23.
EV to Sales22.85
EV to EBITDA-4.79
EV to Free Cash Flow-6.23
EV to Operating Cash Flow-6.31
Balance Sheet
LENZ Therapeutics has $292.35M in cash and marketable securities with $350.00K in debt, giving a net cash position of $292.00M billion.
Cash & Marketable Securities$292.35M
Total Debt$350.00K
Net Cash$292.00M
Net Cash Per Share$9.31
Tangible Book Value Per Share$9.87
Margins
Gross margin is 97.16%, with operating margin of -477.46%, and net profit margin of -430.25%.
Gross Margin97.16%
Operating Margin-477.46%
Pretax Margin-427.62%
Net Profit Margin-430.25%
EBITDA Margin-477.46%
EBIT Margin-477.46%
Analyst Forecast
The average price target for LENZ Therapeutics is $40.34, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$40.34
Price Target Upside317.17% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast70.19%